In this update, we discuss relevant results from selected recent (pre-)clinical studies and in particular the anti-tumor and immunomodulatory effects associated with MEK inhibition to point out its potential in the context of combinatorial and intermittent anticancer therapy. The gene discussed is MAP2K7; the disease is neoplasm.